114P RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS)
m on Q6W combo (p<0.1;n=10), indicating better T-cell functionality in patients with durable benefit. Conclusions:These translational results indicate biological and clinical activity of acasunlimab + pembro in PD-L1+ mNSCLC, supporting a less frequent dosing paradigm (Q6W) to reinvigorate and maintain T-cell functionality post-CPI.
Authors
- S. Peters
- C. Wang
- L. Liu
- G. Han
- L. Cao
- N. Zhao
- X. Lin
- G. Schvartsman
- D. Yue
- M. Provencio Pulla
- M. Austin Taylor
- K. Naicker
- L. Zhang
- H. Liu
Institutions
- Sun Yat-sen University (CN)
- Sichuan University (CN)
- Hospital Israelita Albert Einstein (BR)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- West China Hospital of Sichuan University (CN)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Anhui Provincial Hospital (CN)
- Cambridge in America (US)
- Sun Yat-sen University Cancer Center (CN)
- Hubei Cancer Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- University of Lausanne (CH)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106421
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00